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initiation of the immune response seems to take place.
These findings from a murine GN model suggest that the
transfer of in vitro expanded autologous Treg might rep-
resent a new treatment option in human GN.
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Aldosterone-mediated
endothelial remodeling and
oxidative stress
To the Editor: The recognition of the inflamma-
tory and profibrotic role of aldosterone in the patho-
physiology of cardiovascular disease, via its effect on
endothelial dysfunction, is of growing importance, as
demonstrated by the results of the recently concluded
Randomized Aldactone Evaluation Study (RALES)
[1], and the EPlerenone neuroHormonal Efficacy and
SUrvival Study (EPHESUS) [2]. These studies have,
in fact, indicated the reduction of aldosterone effects
through receptor blocking as additional benefit to pa-
tients with cardiovascular diseases.
In a paper published in the May issue Kidney Inter-
national, Oberleithner documented “in vitro” an aldos-
terone remodeling effect on human endothelium through
induction of cell stiffness due to a presumably aldosterone
induced oxidative stress via modulation of NAD(P)H ox-
idase [3]. We would like to provide further support to the
contention of a specific remodeling and profibrotic ac-
tion of aldosterone with the demonstration “ex vivo” in
human mononuclear cells, recently published by our lab-
oratory [4], that indicates that aldosterone has a direct
effect on oxidative stress through its ability to increase
the levels of p22phox, an important subunit of NADPH
oxidase, essential for superoxide anion generation. It, in
fact, functions as an integral subunit of the final electron
transport from NADPH to heme and molecular oxygen in
generating superoxide anions. The aldosterone-induced
increased level of PAI-1, a recognized profibrotic protein,
we have shown in the same study [4], may also provide a
direct link to the cardiovascular profibrotic and remod-
eling action of aldosterone. Our findings were further
strengthened by similar effects shown by glycyrrhetinic
acid [4], a constituent of licorice root, which is known to
have a direct mineralocorticoid-like effect [5]. Thus, the
report of Oberleithner [3] in combination with the results
of our study provides clear evidence for the aldosterone-
related vascular remodeling effects through its induction
of oxidative stress and oxidative stress-related profibrotic
molecules, such as PAI-1 [4].
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Screening for
microalbuminuria
In their recent contributions to Kidney International,
de Zeeuw [1], as well as de Jong and Brenner [2], argue
that primary prevention of cardiovascular and renal dis-
ease may be possible by lowering albumin excretion in
